Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 12/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 1.00 |
| ▸ | SLC10A2 | Q12908 | 3/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 2/20 | 1.00 |
| ▸ | PLA2G1B | P04054 | 1/20 | 1.00 |
| ▸ | SLC10A1 | Q14973 | 6/20 | 0.89 |
| ▸ | VDR | P11473 | 1/20 | 0.79 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taurochenodeoxycholate SCHEMBL9152921 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL4411471 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL13094131 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL12917602 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL24001493 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL40763 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL24435723 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL17641266 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL24015433 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL17309129 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373496-A1 | COMPOSITION OR FORMULATION COMPRISING ONE OR MORE 5-ALPHA-REDUCTASE INHIBITORS AND ONE OR MORE BILE ACIDS | S&R Farmaceutici S.p.A. (IT) | 2024-05-29 | — | — | EP | claimed |
| EP-4351544-A1 | USE OF STOICHIOMETRIC COMBINATION OF RESVERATROL AND BILE ACIDS FOR TOPICAL TREATMENT OF NEUROGENIC INFLAMMATION AND ITCHING | S&R Farmaceutici S.p.A. (IT) | 2024-04-17 | — | — | EP | claimed |
| WO-2022259179-A1 | USE OF STOICHIOMETRIC COMBINATION OF RESVERATROL AND BILE ACIDS FOR TOPICAL TREATMENT OF NEUROGENIC INFLAMMATION AND ITCHING | S&R FARMACEUTICI S.P.A. (IT) | 2022-12-15 | — | — | WO | claimed |
| WO-2022185228-A1 | COMPOSITION OR FORMULATION COMPRISING ONE OR MORE 5-ALPHA-REDUCTASE INHIBITORS AND ONE OR MORE BILE ACIDS | S&R FARMACEUTICI S.P.A. (IT) | 2022-09-09 | — | — | WO | claimed |
| EP-0359058-A1 | 2-Hydoxy-N,N,N-trimethyl-ethanaminium salts of 5-beta-cholan-24-oic acid | Diamalt GmbH (DE) | 1990-03-21 | — | — | EP | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260085364-A1 | USE OF BIOMARKERS IN TREATMENT WITH BIFIDOBACTERIA | INT N&H DENMARK APS (DK) | 2026-03-26 | — | — | US | disclosed |
| CN-119385862-A | Application of bioconversion bear gall powder in preparation of cosmetics and cosmetics | 株式会社尚食 | 2025-02-07 | — | — | CN | disclosed |
| CN-119120267-A | Application of breast milk-derived lactobacillus gasseri in weight reduction, blood lipid reduction, type 2 diabetes prevention and treatment, intestinal leakage relief and intestinal pathogenic bacteria inhibition | 尚品健康科技(青岛)有限公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-4373496-A1 | COMPOSITION OR FORMULATION COMPRISING ONE OR MORE 5-ALPHA-REDUCTASE INHIBITORS AND ONE OR MORE BILE ACIDS | S&R Farmaceutici S.p.A. (IT) | 2024-05-29 | — | — | EP | disclosed |
| EP-4351544-A1 | USE OF STOICHIOMETRIC COMBINATION OF RESVERATROL AND BILE ACIDS FOR TOPICAL TREATMENT OF NEUROGENIC INFLAMMATION AND ITCHING | S&R Farmaceutici S.p.A. (IT) | 2024-04-17 | — | — | EP | disclosed |
| CN-116747301-A | Application of bile acid substance and animal bile product in preparing radiotherapy sensitizer | 黑龙江中医药大学 | 2023-09-15 | — | — | CN | disclosed |
| EP-2449488-A1 | METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES | BIOCRATES Life Sciences AG (AT) | 2012-05-09 | — | — | EP | disclosed |
| EP-2427773-A1 | METHOD OF DIAGNOSING ASPHYXIA | Keller, Matthias (DE) | 2012-03-14 | — | — | EP | disclosed |
| US-20110280847-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CLOSTRIDIUM DIFFICILE SPORE GERMINATION AND OUTGROWTH | TUFTS UNIVERSITY (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2011000753-A1 | METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES | BIOCRATES LIFE SCIENCES AG (AT) | 2011-01-06 | — | — | WO | disclosed |
| EP-2270699-A1 | Method for normalization in metabolomics analysis methods with endogenous reference metabolites | BIOCRATES Life Sciences AG (AT) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010128054-A1 | METHOD OF DIAGNOSING ASPHYXIA | BIOCRATES LIFE SCIENCES AG (AT) | 2010-11-11 | — | — | WO | disclosed |
| EP-0387325-B1 | 2-HYDROXY-N,N,N-TRIMETHYLETHANAMINIUM SALTS OF 5$g(b)-CHOLANE-24-ACID DERIVATES | PHARMORGANA GMBH (DE) | 1995-02-08 | — | — | EP | disclosed |
| EP-0359058-A1 | 2-Hydoxy-N,N,N-trimethyl-ethanaminium salts of 5-beta-cholan-24-oic acid | Diamalt GmbH (DE) | 1990-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280847-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CLOSTRIDIUM DIFFICILE SPORE GERMINATION AND OUTGROWTH | SLC10A2, CDC37, NR1H4 | GPBAR1 17/4885NR1H4 3/4885SLC10A2 1/4885 |
| US-20260085364-A1 | USE OF BIOMARKERS IN TREATMENT WITH BIFIDOBACTERIA | FABP2, ALPI, CES1 | GPBAR1 58/4885NR1H4 68/4885SLC10A2 162/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | GPBAR1 2130/4885NR1H4 1313/4885SLC10A2 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.